Terms: = Uterine cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Diagnosis
15 results:
1. Identification of a prognostic model based on immune and hypoxia-related gene expressions in cervical cancer.
Wang L; Wang C; He Y; Jin M; Lin L; Jiao X; Hu X; Wang Y
J Obstet Gynaecol; 2023 Dec; 43(2):2277242. PubMed ID: 37938121
[TBL] [Abstract] [Full Text] [Related]
2. Management of trophoblastic tumors : review of evidence, current practice, and future directions.
Deleuze A; Massard C; Le Du F; You B; Lefeuvre-Plesse C; Bolze PA; de la Motte Rouge T
Expert Rev Anticancer Ther; 2023 Jul; 23(7):699-708. PubMed ID: 37198729
[TBL] [Abstract] [Full Text] [Related]
3. Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma.
Walker CA; Spirtos AN; Miller DS
Expert Rev Anticancer Ther; 2023 Apr; 23(4):361-368. PubMed ID: 36944439
[TBL] [Abstract] [Full Text] [Related]
4. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
[TBL] [Abstract] [Full Text] [Related]
5. Pan-cancer Gene Analysis of m6A Modification and Immune Infiltration in uterine Corpus Endometrial Carcinoma.
Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
[TBL] [Abstract] [Full Text] [Related]
6. Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients.
Omenai SA; Ajani MA; Okolo CA
PLoS One; 2022; 17(2):e0263615. PubMed ID: 35139126
[TBL] [Abstract] [Full Text] [Related]
7. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
[TBL] [Abstract] [Full Text] [Related]
8. Clinical and pathological analysis of companion diagnostic testing of microsatellite instability-high for pembrolizumab in gynaecologic malignancy.
Takeda T; Tsuji K; Kobayashi Y; Banno K; Aoki D
Jpn J Clin Oncol; 2022 Feb; 52(2):128-133. PubMed ID: 34750611
[TBL] [Abstract] [Full Text] [Related]
9. MiR-374b increases the CIK expression and mediates biological function changes in cervical cancer cells by targeting the pd-1/PD-L1 signaling pathway.
Wang C; Kuang L; Han L
J Reprod Immunol; 2021 Feb; 143():103265. PubMed ID: 33360511
[TBL] [Abstract] [Full Text] [Related]
10. Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer.
Zhang Y; Yu M; Jing Y; Cheng J; Zhang C; Cheng L; Lu H; Cai MC; Wu J; Wang W; Lou W; Qiu L; Tan L; Lu H; Yin X; Zhuang G; Di W
Br J Cancer; 2021 Jan; 124(2):414-424. PubMed ID: 33087896
[TBL] [Abstract] [Full Text] [Related]
11. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/pd-1) in HPV-induced Cervical cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract] [Full Text] [Related]
12. Anti-programmed Death-1 Immunotherapy for Endometrial cancer with Microsatellite Instability-High Tumors.
Sobecki-Rausch J; Barroilhet L
Curr Treat Options Oncol; 2019 Nov; 20(11):83. PubMed ID: 31754884
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic significance of PD-L1 protein expression and copy number gains in locally advanced cervical cancer.
Loharamtaweethong K; Supakatitham C; Vinyuvat S; Puripat N; Tanvanich S; Sitthivilai U
Asian Pac J Allergy Immunol; 2021 Dec; 39(4):309-318. PubMed ID: 31586491
[TBL] [Abstract] [Full Text] [Related]
14. Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience.
Indini A; Di Guardo L; Cimminiello C; Lorusso D; Raspagliesi F; Del Vecchio M
J Gynecol Oncol; 2019 Nov; 30(6):e94. PubMed ID: 31576688
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Inaguma S; Wang Z; Lasota J; Sarlomo-Rikala M; McCue PA; Ikeda H; Miettinen M
Am J Surg Pathol; 2016 Aug; 40(8):1133-42. PubMed ID: 27158757
[TBL] [Abstract] [Full Text] [Related]
